ISSN: 2578-4625
Authors: Hugwil AV*
CLN-IgG (Pritumuab) was subjected to clinical trials aiming at regression of brain tumors. The mechanism underlying the dramatic recuperation of cancer patient was considered by means of augmentation of idiotypic antibody-mediated internal image transmission of the vimentin epitope-vipidam. Silencing of prionogenicity of vimentin by chaperonic antibody CLN-IgG was a pertinent modality to elongate cancer patient's senescence with little side effect.
Keywords: Vimentin Epitope; Cancer Stem Cell; Chaperonic Antibody; EMT/MET; Prion; Liquid- Droplets; Amylome; Coacervate; Idiotypic Antibody; Immune Clock; Anti-cancer antibody Pritumumab
